Empagliflozin (Jardiance®) is indicated for the treatment of symptomatic chronic heart failure with reduced ejection fraction.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||05/07/2021|
|Rapid review completed||29/07/2021|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of empagliflozin compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by HSE||24/08/2021|
|Pre-submission consultation with Applicant||18/10/2021|
|Full submission received from Applicant||12/01/2022|
|Preliminary Review sent to Applicant||28/02/2022|
|NCPE assessment re-commenced||28/03/2022|
|Factual Accuracy Check sent to Applicant||30/03/2022|
|NCPE assessment re-commenced||07/04/2022|
|NCPE assessment completed||28/04/2022|
|NCPE assessment outcome||
The NCPE considers empagliflozin to be a cost-effective treatment for adults with symptomatic chronic heart failure with reduced ejection fraction and reimbursement is recommended*.
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.